The Joint Pain Injections market size was valued at USD 2,680.0 million in 2018 to USD 3,485.1 million in 2024 and is anticipated to reach USD 6,253.3 million by 2032, at a CAGR of 7.63% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Joint Pain Injections Market Size 2024
USD 3,485.1 Million
Joint Pain Injections Market, CAGR
7.63%
Joint Pain Injections Market Size 2032
USD 6,253.3 Million
The joint pain injections market is led by global players such as Anika Therapeutics, Arthrex, Bioventus, Pacira BioSciences (Flexion), Pfizer, Sanofi, Stryker Corporation, and Zimmer Biomet Holdings. These companies hold strong portfolios in corticosteroid, hyaluronic acid, and biologic-based injections, supported by strategic investments in R&D and clinical trials for advanced regenerative therapies. North America emerged as the leading region in 2024, commanding a 40.9% market share, driven by high adoption of minimally invasive treatments, strong reimbursement frameworks, and well-established healthcare infrastructure. Europe followed with a 24.1% share, supported by aging demographics and favorable insurance systems. Asia Pacific, with 23.0% share and the fastest growth rate, is poised to become a major future hub, propelled by rising healthcare access, growing prevalence of osteoarthritis, and expanding medical tourism.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Joint Pain Injections market was valued at USD 3,485.1 million in 2024 and is projected to reach USD 6,253.3 million by 2032, expanding at a CAGR of 7.63%.
Rising prevalence of osteoarthritis and rheumatoid arthritis, combined with growing demand for minimally invasive pain management solutions, drives market expansion across both developed and developing regions.
Key trends include increasing adoption of platelet-rich plasma (PRP) and biologic injections, alongside technological advancements in guided delivery methods that improve precision and treatment outcomes.
The competitive landscape features strong players such as Anika Therapeutics, Arthrex, Bioventus, Pfizer, Sanofi, Stryker, and Zimmer Biomet, with smaller firms focusing on niche biologics and affordable viscosupplementation therapies to capture regional demand.
North America leads with 40.9% share, followed by Europe at 24.1% and Asia Pacific at 23.0%, while knee and ankle applications dominate with nearly 45% share, highlighting the central role of osteoarthritis in shaping demand patterns.
Market Segmentation Analysis:
By Type
Steroid joint injections dominated the market in 2024 with over 40% share, owing to their widespread use for immediate pain relief and inflammation reduction in osteoarthritis and rheumatoid arthritis patients. Their low cost, proven efficacy, and easy availability through healthcare facilities further strengthen adoption. Hyaluronic acid injections are gaining steady traction as viscosupplementation therapies, particularly for knee osteoarthritis. Platelet-rich plasma (PRP) injections are expanding in demand due to regenerative benefits, while the “Others” category, including biologics, remains a niche but emerging segment driven by innovation in advanced pain therapies.
For instance, Depo-Medrol (methylprednisolone acetate) is a product manufactured by Pfizer and is used for various conditions, including joint pain therapy. The company distributes this drug internationally.
By Application
Knee and ankle applications accounted for the largest share of the joint pain injections market in 2024, representing nearly 45%. High prevalence of knee osteoarthritis among the aging population and sports-related ankle injuries fuel demand. Shoulder and elbow injections are also widely used for athletes and patients with repetitive stress injuries. Spinal joint injections, though smaller in share, show growth due to increasing cases of chronic back pain. The “Others” category, covering small joints, reflects niche use but highlights future opportunities as broader musculoskeletal conditions are targeted.
For instance, Flexion Therapeutics developed ZILRETTA (extended-release triamcinolone acetonide) for knee OA; in its Phase 3 trial, patients reported pain relief sustained through 12 weeks and some through 16 weeks post injection.
By Distribution Channel
Hospital pharmacies held the dominant share of more than 50% in 2024, reflecting patient reliance on hospital-based treatments and prescribed therapies for joint pain. Their leadership is supported by specialist consultations, availability of advanced injections, and insurance coverage in many regions. Retail pharmacies follow, catering to patients seeking convenient access for refills. Online pharmacies are emerging as a fast-growing channel, particularly in developed economies, driven by digital healthcare expansion and home delivery services. The “Others” category includes specialty clinics and rehabilitation centers, adding to distribution diversity.
Key Growth Drivers
Rising Prevalence of Osteoarthritis and Chronic Joint Disorders
The increasing prevalence of osteoarthritis, rheumatoid arthritis, and sports-related joint injuries stands as the leading driver of the joint pain injections market. According to global health estimates, osteoarthritis affects millions of aging adults worldwide, leading to significant functional limitations and demand for effective pain management. Steroid and hyaluronic acid injections are widely adopted as first-line non-surgical interventions, reducing inflammation and improving mobility. Growing awareness of early treatment options, coupled with rising life expectancy and sedentary lifestyles, continues to boost patient volumes. In emerging economies, improved diagnostic rates and expansion of healthcare access further accelerate demand for intra-articular injections.
For instance, Anika Therapeutics reported that its Cingal® (hyaluronic acid + triamcinolone hexacetonide) resulted in a 70% improvement from baseline in WOMAC pain scores at 12 weeks, in a randomized trial of 368 patients with knee osteoarthritis.
Shift Toward Minimally Invasive and Regenerative Therapies
Growing preference for minimally invasive pain management solutions is driving adoption of joint pain injections. Patients increasingly opt for injections over surgical interventions due to shorter recovery times, lower risks, and cost advantages. Platelet-rich plasma (PRP) injections are gaining traction as regenerative therapies, offering tissue-healing potential and long-term relief for athletes and elderly patients alike. Clinical evidence supporting Visco supplementation with hyaluronic acid in knee osteoarthritis adds further credibility. Demand is also propelled by technological advancements in guided injection techniques, including ultrasound and fluoroscopy, which improve precision and efficacy. This shift highlights a long-term trend toward safer, innovative treatment solutions.
For example, in a specific 2021 study involving 70 patients with early knee osteoarthritis, PRP injections resulted in a significant increase in the mean IKDC score from a baseline of 38.99 to 63.86 at 6 months.
Expansion of Healthcare Infrastructure and Insurance Coverage
The growing accessibility of healthcare services, supported by infrastructure expansion and favorable reimbursement policies, fuels market growth. In developed regions, insurance coverage for corticosteroid and hyaluronic acid injections encourages higher adoption rates among patients seeking affordable care. Hospital pharmacies play a major role, ensuring consistent access to advanced therapies under physician supervision. In developing regions, public health programs are increasingly emphasizing musculoskeletal health and pain management, boosting awareness of injection-based treatments. Combined with rising disposable incomes and investments in healthcare modernization, these factors create a supportive environment for sustained market growth across diverse patient populations.
Key Trends & Opportunities
Technological Advancements in Biologic and Next-Generation Therapies
Emerging biologic therapies, including stem-cell-based injections and advanced PRP formulations, are reshaping the competitive landscape. These treatments focus not only on symptom relief but also on repairing damaged tissues and slowing disease progression. With ongoing clinical trials and regulatory approvals, next-generation joint pain injections are expected to expand therapeutic options, especially for patients unresponsive to conventional treatments. Strategic collaborations between biotech firms and medical device companies further accelerate innovation. This trend creates opportunities for players to differentiate their portfolios and capture high-value segments within the growing regenerative medicine field.
For instance, CartiHeal’s Agili-C™ implant, evaluated in a pivotal IDE trial of 251 patients, showed 80% responder rates in knee osteoarthritis at 24 months, outperforming microfracture techniques.
Growth Potential in Emerging Economies
Developing markets in Asia-Pacific, Latin America, and the Middle East present significant untapped opportunities. Rising urbanization, increasing life expectancy, and greater incidence of lifestyle-related joint disorders are fueling demand. At the same time, governments are investing in healthcare infrastructure and expanding insurance systems, making advanced therapies more accessible. Local players are also entering the market, providing cost-effective joint injection solutions that appeal to price-sensitive patients. This creates a dual opportunity: multinational companies can expand footprints through partnerships, while regional manufacturers can scale affordable alternatives. Collectively, these dynamics strengthen growth prospects in emerging economies.
Key Challenges
High Cost of Advanced Biologic and Regenerative Therapies
Despite growing demand, affordability remains a major barrier, particularly for biologic and regenerative injections like PRP and stem-cell therapies. These treatments are often priced significantly higher than conventional corticosteroid or hyaluronic acid injections, limiting accessibility for middle- and low-income populations. Insurance coverage is inconsistent, with many plans excluding advanced therapies, further restricting adoption. The high cost of research, clinical validation, and regulatory compliance also inflates pricing, preventing widespread availability. Unless pricing models and reimbursement frameworks evolve, adoption of next-generation injections may remain restricted to premium patient segments in developed markets.
Regulatory and Clinical Validation Challenges
Regulatory hurdles and limited long-term clinical evidence present another challenge in the joint pain injections market. While corticosteroid and hyaluronic acid injections are well established, newer options like PRP and stem-cell therapies face stricter scrutiny. Inconsistent guidelines across regions create uncertainty for manufacturers and healthcare providers. Additionally, the lack of large-scale, randomized clinical trials hinders broader acceptance among physicians and payers. Safety concerns and varying efficacy outcomes also contribute to hesitation in adoption. Addressing these challenges requires stronger clinical evidence, harmonized regulatory pathways, and transparent communication of therapeutic benefits to ensure trust and broader adoption.
Regional Analysis
North America
North America led the joint pain injections market in 2024 with a 40.9% share, valued at USD 1,424.70 million, up from USD 1,107.38 million in 2018. The region is projected to reach USD 2,553.23 million by 2032, registering a 7.6% CAGR. Strong adoption of corticosteroid and hyaluronic acid injections, robust healthcare infrastructure, and favorable reimbursement policies drive this dominance. The prevalence of osteoarthritis among the aging population further strengthens demand, while ongoing clinical trials for regenerative injections, including PRP and biologics, add to the region’s long-term growth potential.
Europe
Europe accounted for 24.1% of the global market in 2024, reaching USD 839.12 million, compared with USD 672.68 million in 2018. The market is expected to grow to USD 1,417.95 million by 2032 at a 6.8% CAGR. Growth is driven by an increasing elderly population, rising osteoarthritis prevalence, and wider access to viscosupplementation therapies. Countries like Germany, France, and the UK remain major markets due to established insurance systems. While regulatory approvals for regenerative injections are slower, strong clinical adoption of established corticosteroid injections sustains Europe’s competitive position in the global landscape.
Asia Pacific
Asia Pacific held 23.0% of the global market in 2024, valued at USD 800.00 million, rising from USD 586.12 million in 2018. The market is forecasted to nearly double to USD 1,600.85 million by 2032, expanding at the fastest regional CAGR of 9.1%. Rapid urbanization, increasing life expectancy, and higher incidences of joint disorders drive demand. Expanding healthcare infrastructure, coupled with rising medical tourism in countries like India and Thailand, supports adoption. Additionally, cost-effective manufacturing and growing acceptance of regenerative therapies position Asia Pacific as a high-growth region with significant long-term opportunities for both global and local players.
Latin America
Latin America contributed 5.4% of the global market in 2024, generating USD 188.16 million, compared with USD 146.33 million in 2018. By 2032, the market is anticipated to reach USD 309.35 million, growing at a 6.5% CAGR. Demand is supported by an expanding middle-class population, greater healthcare investments, and increasing awareness of joint pain management solutions. Brazil and Mexico remain key growth hubs, offering both private and public sector opportunities. However, limited reimbursement for advanced biologic injections remains a barrier, though rising uptake of corticosteroid therapies ensures consistent demand across the region.
Middle East
The Middle East represented 3.9% of the global market in 2024, valued at USD 134.50 million, rising from USD 109.88 million in 2018. The market is forecasted to reach USD 219.53 million by 2032, reflecting a 6.4% CAGR. Rising cases of lifestyle-related joint conditions, coupled with growing adoption of advanced orthopedic care in countries like Saudi Arabia and the UAE, support demand. Increasing investments in hospital infrastructure and the rise of medical tourism further drive market expansion. Despite higher costs of regenerative therapies, established corticosteroid and hyaluronic acid injections maintain steady adoption across the region.
Africa
Africa accounted for the smallest share at 2.8% in 2024, reaching USD 98.64 million, up from USD 57.62 million in 2018. By 2032, the market is projected to grow to USD 152.39 million, recording a 5.2% CAGR. Growth is driven by rising awareness of musculoskeletal disorders and gradual expansion of healthcare access. South Africa remains the largest contributor, followed by Nigeria and Egypt, where urban populations are increasingly adopting non-surgical pain management solutions. However, limited affordability and lack of insurance coverage for advanced biologics continue to hinder wider adoption, leaving corticosteroid injections as the primary treatment option.
Market Segmentations:
By Type
Steroid Joint Injections
Hyaluronic Acid Injections
Platelet-Rich Plasma (PRP) Injections
Others
By Application
Shoulder & Elbow
Knee & Ankle
Spinal Joints
Others
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Competitive Landscape
The joint pain injections market is moderately consolidated, with leading players focusing on innovation, strategic collaborations, and geographic expansion to strengthen their positions. Key companies such as Anika Therapeutics, Arthrex, Bioventus, Pacira BioSciences (Flexion), Pfizer, Sanofi, Stryker, and Zimmer Biomet dominate through extensive product portfolios spanning corticosteroid, hyaluronic acid, and biologic injections. These players invest heavily in clinical research and regulatory approvals, particularly for platelet-rich plasma (PRP) and next-generation regenerative therapies, to address growing demand for minimally invasive solutions. Mid-sized companies like Emcyte, OrthogenRx, and Lifecore Biomedical compete by offering niche biologics and cost-effective viscosupplementation products, while Ferring B.V. strengthens its presence with global partnerships. Market competition is also shaped by pricing strategies, distribution networks, and reimbursement coverage, especially in North America and Europe. Emerging players in Asia-Pacific and Latin America focus on affordability, providing opportunities for regional expansion. Overall, innovation, clinical validation, and accessibility remain key competitive differentiators across the market.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In December 2023, Bioventus agreed to a nationwide contract with Aetna Medicare Advantage plans, wherein over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE, single-injection hyaluronic acid (HA)-based joint-fluid treatment, to treat knee osteoarthritis (OA).
In November 2022, Anika Therapeutics, Inc. announced that its product Cingal demonstrated positive results in phase III clinical trials and is planning to proceed further for the U.S. FDA approval.
In March 2022, Sanofi collaborated with IGM Biosciences Inc. to develop, manufacture, and introduce potential therapeutics in the fields of immunology and inflammation.
In January 2022, SEIKAGAKU CORPORATION announced the establishment of a new company in Canada, SEIKAGAKU NORTH AMERICA CORPORATION, with an aim to expand its geographical presence.
Report Coverage
The research report offers an in-depth analysis based on Type, Application, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The market will expand steadily with rising cases of osteoarthritis and joint disorders.
Demand for minimally invasive treatments will increase over surgical alternatives.
Platelet-rich plasma and biologic injections will gain wider clinical acceptance.
Hyaluronic acid injections will remain important for knee osteoarthritis therapies.
North America will continue to lead due to advanced healthcare and reimbursement.
Asia Pacific will grow fastest, supported by medical tourism and infrastructure development.
Online pharmacies will rise as a preferred channel for patient convenience.
Regulatory clarity will shape adoption of next-generation regenerative therapies.
Competition will intensify as global and regional players diversify portfolios.
Affordability and broader insurance coverage will decide access in emerging markets.
CHAPTER NO. 4 : KEY INVESTMENT EPICENTER
4.1 Regional Goldmines – High-Growth Geographies
4.2 Product Frontiers – Lucrative Product Categories
4.3 Application Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Regional Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Type & Application Revenue CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Region
6.1.1. Global Joint Pain Injections Market Import Revenue By Region
6.2. Export Analysis by Region
6.2.1. Global Joint Pain Injections Market Export Revenue By Region CHAPTER NO. 7 : COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Global Joint Pain Injections Market: Company Market Share
7.2. Global Joint Pain Injections Market Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Product Launch
7.3.3. Regional Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8 : JOINT PAIN INJECTIONS MARKET – BY TYPE SEGMENT ANALYSIS
8.1. Joint Pain Injections Market Overview by Type Segment
8.1.1. Joint Pain Injections Market Revenue Share By Type
8.2. Steroid Joint Injections
8.3. Hyaluronic Acid Injections
8.4. Platelet-Rich Plasma (PRP) Injections
8.5. Others CHAPTER NO. 9 : JOINT PAIN INJECTIONS MARKET – BY APPLICATION SEGMENT ANALYSIS
9.1. Joint Pain Injections Market Overview by Application Segment
9.1.1. Joint Pain Injections Market Revenue Share By Application
9.2. Shoulder & Elbow
9.3. Knee & Ankle
9.4 Spinal Joints
9.5. Others CHAPTER NO. 10 : JOINT PAIN INJECTIONS MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS
10.1. Joint Pain Injections Market Overview by Distribution Channel Segment
10.1.1. Joint Pain Injections Market Revenue Share By Distribution Channel
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.5. Others CHAPTER NO. 11 : JOINT PAIN INJECTIONS MARKET – REGIONAL ANALYSIS
11.1. Joint Pain Injections Market Overview by Region Segment
11.1.1. Global Joint Pain Injections Market Revenue Share By Region
11.1.3. Regions
11.1.4. Global Joint Pain Injections Market Revenue By Region
.1.6. Type
11.1.7. Global Joint Pain Injections Market Revenue By Type
11.1.9. Application
11.1.10. Global Joint Pain Injections Market Revenue By Application
11.1.12. Distribution Channel
11.1.13. Global Joint Pain Injections Market Revenue By Distribution Channel CHAPTER NO. 12 : NORTH AMERICA JOINT PAIN INJECTIONS MARKET – COUNTRY ANALYSIS
12.1. North America Joint Pain Injections Market Overview by Country Segment
12.1.1. North America Joint Pain Injections Market Revenue Share By Region
12.2. North America
12.2.1. North America Joint Pain Injections Market Revenue By Country
12.2.2. Type
12.2.3. North America Joint Pain Injections Market Revenue By Type
12.2.4. Application
12.2.5. North America Joint Pain Injections Market Revenue By Application
2.2.6. Distribution Channel
12.2.7. North America Joint Pain Injections Market Revenue By Distribution Channel
2.3. U.S.
12.4. Canada
12.5. Mexico CHAPTER NO. 13 : EUROPE JOINT PAIN INJECTIONS MARKET – COUNTRY ANALYSIS
13.1. Europe Joint Pain Injections Market Overview by Country Segment
13.1.1. Europe Joint Pain Injections Market Revenue Share By Region
13.2. Europe
13.2.1. Europe Joint Pain Injections Market Revenue By Country
13.2.2. Type
13.2.3. Europe Joint Pain Injections Market Revenue By Type
13.2.4. Application
13.2.5. Europe Joint Pain Injections Market Revenue By Application
13.2.6. Distribution Channel
13.2.7. Europe Joint Pain Injections Market Revenue By Distribution Channel
13.3. UK
13.4. France
13.5. Germany
13.6. Italy
13.7. Spain
13.8. Russia
13.9. Rest of Europe CHAPTER NO. 14 : ASIA PACIFIC JOINT PAIN INJECTIONS MARKET – COUNTRY ANALYSIS
14.1. Asia Pacific Joint Pain Injections Market Overview by Country Segment
14.1.1. Asia Pacific Joint Pain Injections Market Revenue Share By Region
14.2. Asia Pacific
14.2.1. Asia Pacific Joint Pain Injections Market Revenue By Country
14.2.2. Type
14.2.3. Asia Pacific Joint Pain Injections Market Revenue By Type
14.2.4. Application
14.2.5. Asia Pacific Joint Pain Injections Market Revenue By Application
14.2.5. Distribution Channel
14.2.7. Asia Pacific Joint Pain Injections Market Revenue By Distribution Channel
14.3. China
14.4. Japan
14.5. South Korea
14.6. India
14.7. Australia
14.8. Southeast Asia
14.9. Rest of Asia Pacific CHAPTER NO. 15 : LATIN AMERICA JOINT PAIN INJECTIONS MARKET – COUNTRY ANALYSIS
15.1. Latin America Joint Pain Injections Market Overview by Country Segment
15.1.1. Latin America Joint Pain Injections Market Revenue Share By Region
15.2. Latin America
15.2.1. Latin America Joint Pain Injections Market Revenue By Country
15.2.2. Type
15.2.3. Latin America Joint Pain Injections Market Revenue By Type
15.2.4. Application
15.2.5. Latin America Joint Pain Injections Market Revenue By Application
15.2.6. Distribution Channel
15.2.7. Latin America Joint Pain Injections Market Revenue By Distribution Channel
15.3. Brazil
15.4. Argentina
15.5. Rest of Latin America CHAPTER NO. 16 : MIDDLE EAST JOINT PAIN INJECTIONS MARKET – COUNTRY ANALYSIS
16.1. Middle East Joint Pain Injections Market Overview by Country Segment
16.1.1. Middle East Joint Pain Injections Market Revenue Share By Region
16.2. Middle East
16.2.1. Middle East Joint Pain Injections Market Revenue By Country
16.2.2. Type
16.2.3. Middle East Joint Pain Injections Market Revenue By Type
16.2.4. Application
16.2.5. Middle East Joint Pain Injections Market Revenue By Application
16.2.6. Distribution Channel
16.2.7. Middle East Joint Pain Injections Market Revenue By Distribution Channel
16.3. GCC Countries
16.4. Israel
16.5. Turkey
16.6. Rest of Middle East CHAPTER NO. 17 : AFRICA JOINT PAIN INJECTIONS MARKET – COUNTRY ANALYSIS
17.1. Africa Joint Pain Injections Market Overview by Country Segment
17.1.1. Africa Joint Pain Injections Market Revenue Share By Region
17.2. Africa
17.2.1. Africa Joint Pain Injections Market Revenue By Country
17.2.2. Type
17.2.3. Africa Joint Pain Injections Market Revenue By Type
17.2.4. Application
17.2.5. Africa Joint Pain Injections Market Revenue By Application
17.2.6. Distribution Channel
17.2.7. Africa Joint Pain Injections Market Revenue By Distribution Channel
17.3. South Africa
17.4. Egypt
17.5. Rest of Africa CHAPTER NO. 18 : COMPANY PROFILES
18.1. Anika Therapeutics, Inc.
18.1.1. Company Overview
18.1.2. Product Portfolio
18.1.3. Financial Overview
18.1.4. Recent Developments
18.1.5. Growth Strategy
18.1.6. SWOT Analysis
18.2. Arthrex
18.3. Bioventus
18.4. Emcyte Corporation
18.5. Ferring B.V.
18.6. Lifecore Biomedical
18.7. OrthogenRx
18.8. Pacira BioSciences (Flexion)
18.9. Pfizer, Inc.
18.10. Sanofi S.A.
18.11. Stryker Corporation
18.12. Zimmer Biomet Holdings, Inc.
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Joint Pain Injections market, and what is its projected size in 2032?
The market size was USD 3,485.1 million in 2024 and is projected to reach USD 6,253.3 million by 2032.
At what Compound Annual Growth Rate is the Joint Pain Injections market projected to grow between 2025 and 2032?
The market is forecast to grow at a CAGR of 7.63% during 2025–2032.
Which Joint Pain Injections market segment held the largest share in 2024?
The steroid joint injections segment led in 2024 with over 40% market share.
What are the primary factors fueling the growth of the Joint Pain Injections market?
Rising osteoarthritis prevalence, growing demand for minimally invasive treatments, and improved healthcare access drive growth.
Who are the leading companies in the Joint Pain Injections market?
Key players include Anika Therapeutics, Arthrex, Bioventus, Pacira BioSciences, Pfizer, Sanofi, Stryker, and Zimmer Biomet.
Which region commanded the largest share of the Joint Pain Injections market in 2024?
North America led in 2024 with a 40.9% share, driven by strong adoption and robust reimbursement systems.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Fabry Disease Therapeutic Market has witnessed steady growth in recent years and is expected to grow at a CAGR of 8.80% between 2024 and 2032. The market was valued at USD 1725.8 million in 2023 and is expected to reach USD 3686.8 million in 2032.
The Foot and Mouth Disease (FMD) Vaccines market size was valued at USD 2.68 billion in 2024 and is projected to reach USD 4.78 billion by 2032, growing at a CAGR of 7.5% during the forecast period.
The Idiopathic Pulmonary Fibrosis (IPF) Treatment market was valued at USD 3.25 billion in 2024 and is projected to reach USD 5.66 billion by 2032, expanding at a CAGR of 7.2% during the forecast period.
Hyperhidrosis Treatment Market size was valued USD 2.8 billion in 2024 and is anticipated to reach USD 4.4 billion by 2032, at a CAGR of 5.8% during the forecast period.
The Hyperlipidemia Drugs market was valued at USD 15.2 billion in 2024 and is projected to reach USD 24.04 billion by 2032, expanding at a CAGR of 5.9% during the forecast period.
Bone Glue Market size was valued at USD 930.00 million in 2018, reached USD 1,108.36 million in 2024, and is anticipated to reach USD 1,886.27 million by 2032, at a CAGR of 7.01% during the forecast period.
Global Virtual PLC and Soft PLC in Pharmaceutical market size was valued at USD 149.2 million in 2018 and grew to USD 266.9 million in 2024. It is anticipated to reach USD 649.1 million by 2032, expanding at a CAGR of 11.90% during the forecast period.
The Europe Pharmaceutical Contract Sales Organizations Market is projected to grow from USD 2,635.17 million in 2024 to an estimated USD 4,772.90 million by 2032, with a compound annual growth rate (CAGR) of 7.71% from 2024 to 2032.
The Global Thebaine Market size was valued at USD 89.4 million in 2018 to USD 131.4 million in 2024 and is anticipated to reach USD 222.1 million by 2032, at a CAGR of 6.81% during the forecast period.
The Specialty Pharmaceuticals Market size was valued at USD 225.73 billion in 2024 and is anticipated to reach USD 1461.55 billion by 2032, at a CAGR of 26.3% during the forecast period (2024-2032).
The PET packaging in pharmaceutical market was valued at USD 7,498.00 million in 2024 and is projected to reach USD 11,162.65 million by 2032, growing at a CAGR of 5.1% during the forecast period.
Whole Genome Sequencing Market size was valued USD 2.23 billion in 2024 and is anticipated to reach USD 10.86 billion by 2032, at a CAGR of 21.9% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
